Navin Fluorine International Limited reported a 108% year-on-year rise in consolidated net profit for the first quarter of FY27, reaching ₹243.3 crore. The company also announced it will host analyst and investor meetings on September 16 and 17, 2026, at the Jefferies India Forum.

Consolidated revenue from operations grew 44% to ₹1,045.1 crore, supported by volume growth and higher realizations across its business verticals. Operating EBITDA expanded by 73% to ₹357.1 crore, with margins widening by 566 basis points to 34.2%.

Financial Performance

The company’s profitability metrics showed significant improvement across all key lines. Other income contributed ₹35.1 crore to the bottom line, up from ₹13.9 crore in the same period last year.

Standalone net profit rose 69% to ₹190.6 crore, while standalone revenue increased by 28% to ₹694.7 crore. Standalone operating EBITDA margin expanded by 686 basis points to 35.3%.

Segment Growth Drivers

Growth was broad-based across the company’s three primary verticals. The High Performance Products (HPP) segment saw revenue grow by 33%, while Specialty Chemicals rose by 48%. The Contract Development and Manufacturing Organisation (CDMO) segment led the charge with an 82% increase in revenue, reaching ₹180 crore from ₹99 crore in Q1FY26.

The geographic mix remains balanced, with international markets accounting for 54% of total revenue compared to 46% from domestic sources. In the Specialty Chemicals vertical, international sales constituted 62% of revenue, whereas the CDMO segment is predominantly export-oriented at 98%.

What the Numbers Show

The disproportionate growth in the CDMO segment relative to the overall revenue increase highlights a shifting revenue mix toward higher-margin contract manufacturing services. While overall revenue grew 44%, CDMO revenue nearly doubled, suggesting this vertical is becoming an increasingly significant contributor to the company’s top-line expansion and potentially its future margin profile.

Capacity Expansion Plans

Navin Fluorine is executing a multi-pronged capital expenditure program to support future growth:

• HFC Capacity: An additional capacity equivalent to 15,000 MTPA of R32 is on track for commissioning in Q3FY27, backed by ₹236.5 crore in capex funded by internal accruals.
• CDMO Expansion: Phase II of the cGMP4 capex, valued at ₹125 crore, is expected to be operational by Q4FY27 to meet rising demand from a European client.
• Advanced Materials: The company is incubating a new vertical focused on data centers, electronics, defence, and semiconductors, with ₹90 crore allocated for adoption capacities targeting completion by Q2FY28.
• Chemours Project: Initial commercial capacity for liquid cooling products will be set up with ₹120 crore in capex, 35% of which is customer-funded.

The company emphasized that the pricing environment for Hydrofluorocarbons (HFC) remains constructive, with increasing interest in contractual offtakes for new capacities.

Navin Fluorine International Limited reported a consolidated net profit after tax (PAT) of ₹243.31 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 108% year-on-year surge. The strong performance was driven by a 44% rise in revenue from operations to ₹1,045.08 crore, supported by constructive pricing in hydrofluoroolefins (HFCs), scale-up of specialty chemicals, and deepened engagement with European partners in the Contract Development and Manufacturing Organization (CDMO) segment. During the earnings call on August 05, 2026, management highlighted that the company became net debt-free during the quarter, with operating cash flows standing at ₹173 crore.

The company has scheduled an analyst and institutional investor meet for August 20, 2026, at 10:00 am IST. This intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation to be made at the meeting is based on publicly available information, with discussions expected to cover the recent financial results and strategic initiatives.

The results were filed with stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Price Waterhouse Chartered Accountants LLP provided a limited review report on the unaudited financial results. Chairman Vishad Mafatlal and Managing Director Nitin Kulkarni emphasized the company’s disciplined execution strategy and its transition towards high-margin advanced materials.

Financial Highlights

Operating profitability expanded significantly, with operating EBITDA rising 73% to ₹357.07 crore, pushing the operating EBITDA margin up by 566 basis points to 34.2%. Profit before tax (PBT) jumped 105% to ₹318.36 crore. On a standalone basis, the holding company reported a net profit of ₹190.64 crore, up 69% from ₹112.76 crore in the prior year quarter, while standalone revenue increased 28% to ₹694.68 crore. Net working capital days stood at 81 days of sales.

Segment Performance

Revenue growth was broad-based across all business units:

• HPP: Revenue grew 33% YoY to ₹540 crore, supported by constructive pricing for hydrofluoroolefins (HFCs) and ramp-up of the anhydrous hydrofluoric acid (AHF) facility. Management noted that long-term demand for R32 is expected to double over the next decade while supply shrinks due to quotas.
• Specialty Chemicals: Revenue surged 48% YoY to ₹325 crore, aided by strong order visibility and scale-up of existing molecules. The company has visibility for campaign orders for four to five new molecules in the agrochemical space.
• CDMO: Revenue nearly doubled with an 82% YoY increase to ₹180 crore, driven by deeper engagement with European partners and increased demand for existing molecules. The pipeline includes three more molecules expected to go to FDA readout in the next 8 to 12 months.

Strategic Capex Approvals

The Board approved significant capital expenditures to incubate new growth verticals:

• Advanced Materials: ₹90 crore funded through internal accruals to establish adoption capacities at the Surat unit. This aims to progress products from lab scale to commercial scale qualification by Q2FY28, targeting sectors like data centers, electronics, semiconductors, and defense. This includes a technology development partnership with DRDO for an indigenous specialty material.
• CDMO Expansion: Phase 2 cGMP4 capex of ₹125 crore, also funded through internal accruals, expected to operationalize by Q4FY27. This supports growing demand from a European CDMO partner and expands the footprint in their supply chain to API minus 1 level.
• Other Projects: HFC capacity expansion equivalent to up to 15,000 metric tons of R32 remains on track for commissioning in Q3FY27. A renewable energy project investment of ₹15.73 crore for a 14.9 megawatt hybrid renewable power plant will meet more than 60% of energy requirements through renewable sources once operational.

What the Numbers Show

The divergence between revenue growth (44%) and expense management highlights improved operating leverage for Navin Fluorine International Limited. While raw material costs rose to ₹449.75 crore from ₹307.71 crore, the company successfully contained other expenses, leading to a substantial expansion in operating margins. The CDMO segment’s 82% revenue growth indicates successful execution of its strategy to deepen ties with global innovators, while the HPP segment benefits from favorable global demand-supply dynamics for low-GWP gases. The consistent quarter-on-quarter growth in PAT over the last four quarters underscores sustained operational momentum, further strengthened by the company becoming net debt-free.